Jarra Green-Calderon, APRN
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1659516615
Payments from drug & device makers
Across 254 payments — averaging $760.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$182K
- Cequr Corporation$2K
- Novo Nordisk$2K
- Lilly USA, LLC$926
- AstraZeneca$889
- Mannkind Corporation$849
- plus $5K from 21 others
Across 2 payments — averaging $687.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lexicon Pharmaceuticals, Inc.$1K
What the payments were for
- Speaking & faculty fees$8006%
- Travel & lodging$2,17116%
- Food & beverage$10,37977%
- Education$741%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 15 | $182,048 |
| Cequr Corporation | 4 | $1,750 |
| Novo Nordisk | 33 | $1,713 |
| Lilly USA, LLC | 36 | $926 |
| AstraZeneca | 26 | $889 |
| Mannkind Corporation | 34 | $849 |
| Senseonics, Incorporated | 2 | $800 |
| Dexcom, Inc. | 16 | $793 |
| Corcept Therapeutics | 17 | $607 |
| Averitas Pharma Inc. | 7 | $473 |
| Intuity Medical Inc | 11 | $455 |
| Tandem Diabetes Care, Inc. | 7 | $422 |
| Boehringer Ingelheim | 19 | $356 |
| Xeris Pharmaceuticals, Inc. | 9 | $184 |
| Ascensia Diabetes Care US Inc. | 4 | $181 |
| Zealand Pharma US, Inc. | 1 | $138 |
| Neurocrine Biosciences, Inc. | 1 | $134 |
| Madrigal Pharmaceuticals | 1 | $132 |
| Teva Pharmaceuticals USA, Inc. | 1 | $128 |
| Nestle Healthcare Nutrition Inc. | 3 | $82 |
| Medtronic | 1 | $29 |
| Orpyx Medical Technologies US Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $20 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$1,750
- Eversense$800
- Ozempic$717
- DEXCOM G7 GSS (161)$554
- FARXIGA$491
- Qutenza$397
- Korlym$331
- t:slim X2 Insulin Pump with Control-IQ$243
- Wegovy$242
- Pogo Automatic Blood Glucose Monitoring System$234
- ZEGALOGUE$138
- CRENESSITY$134
- REZDIFFRA$132
- Austedo XR$128
- RYBELSUS$125
- DEXCOM STELO GLUCOSE BIOSENSOR$125
- V-GO$123
- MOUNJARO$117
- DEXCOM G6 TRANSMITTER$100
How this compares
$193,219 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $66,847 |
| TrulicityDulaglutide | 32 | $44,803 |
| JardianceEmpagliflozin | 52 | $36,317 |
| OzempicSemaglutide | 27 | $23,932 |
| FarxigaDapagliflozin Propanediol | 15 | $13,078 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $12,417 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 23 | $9,374 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $8,645 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $6,764 |
| LyumjevInsulin Lispro-Aabc | 12 | $5,527 |
| NovologInsulin Aspart | 12 | $4,506 |
| HumalogInsulin Lispro | 12 | $1,413 |
| Insulin Lispro | 19 | $835 |
| Atorvastatin Calcium | 27 | $216 |
| Rosuvastatin Calcium | 19 | $193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $926 | $119,424139 claims |
| Boehringer IngelheimJardiance | $356 | $36,31752 claims |
| Novo NordiskOzempic, Novolog | $1,713 | $28,43739 claims |
| AstraZenecaFarxiga | $889 | $13,07815 claims |
| Cequr CorporationCequr Simplicity | $1,750 | $9,37423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.